Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.
Sämgård, Kajsa ; Zetterberg, Henrik ; Blennow, Kaj ; Hansson, Oskar LU
; Minthon, Lennart
LU
and Londos, Elisabet
LU
(2010)
In International Journal of Geriatric Psychiatry
25.
p.403-410
- Abstract
- OBJECTIVES: The aim of this longitudinal study was to test the hypothesis that CSF biomarkers in AD patients also may be forward-looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time. METHODS: Here, we assessed the association of CSF Abeta42, T-tau and P-tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3-year prospective longitudinal treatment study. RESULTS: A more rapid progress in MMSE score reduction was seen in AD patients with T-tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's disease patients with... (More)
- OBJECTIVES: The aim of this longitudinal study was to test the hypothesis that CSF biomarkers in AD patients also may be forward-looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time. METHODS: Here, we assessed the association of CSF Abeta42, T-tau and P-tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3-year prospective longitudinal treatment study. RESULTS: A more rapid progress in MMSE score reduction was seen in AD patients with T-tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's disease patients with lower T-tau levels (p = 0.008). We also found that individuals with T-tau > 800 ng/L performed worse in total scores and especially in memory and orientation when assessed with MMSE and ADAS cog than patients with T-tau <800 ng/L. Similar results were obtained for P-tau. No associations were seen between Abeta42 and cognitive scores or disease progression. DISCUSSION: These findings support the hypothesis that increased levels of T-tau reflect the intensity of the disease and are associated with a more rapid disease progress. Copyright (c) 2009 John Wiley & Sons, Ltd. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1470139
- author
- Sämgård, Kajsa
; Zetterberg, Henrik
; Blennow, Kaj
; Hansson, Oskar
LU
; Minthon, Lennart
LU
and Londos, Elisabet
LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Geriatric Psychiatry
- volume
- 25
- pages
- 403 - 410
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000276670000010
- pmid:19650161
- scopus:77949506958
- ISSN
- 1099-1166
- DOI
- 10.1002/gps.2353
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Psychiatry/Primary Care/Public Health (013240500), Clinical Memory Research Unit (013242610)
- id
- 87f60c8f-e0f4-4fd0-ac74-cdee84f7cb17 (old id 1470139)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19650161?dopt=Abstract
- date added to LUP
- 2016-04-04 07:08:29
- date last changed
- 2022-02-13 04:33:54
@article{87f60c8f-e0f4-4fd0-ac74-cdee84f7cb17,
abstract = {{OBJECTIVES: The aim of this longitudinal study was to test the hypothesis that CSF biomarkers in AD patients also may be forward-looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time. METHODS: Here, we assessed the association of CSF Abeta42, T-tau and P-tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3-year prospective longitudinal treatment study. RESULTS: A more rapid progress in MMSE score reduction was seen in AD patients with T-tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's disease patients with lower T-tau levels (p = 0.008). We also found that individuals with T-tau > 800 ng/L performed worse in total scores and especially in memory and orientation when assessed with MMSE and ADAS cog than patients with T-tau <800 ng/L. Similar results were obtained for P-tau. No associations were seen between Abeta42 and cognitive scores or disease progression. DISCUSSION: These findings support the hypothesis that increased levels of T-tau reflect the intensity of the disease and are associated with a more rapid disease progress. Copyright (c) 2009 John Wiley & Sons, Ltd.}},
author = {{Sämgård, Kajsa and Zetterberg, Henrik and Blennow, Kaj and Hansson, Oskar and Minthon, Lennart and Londos, Elisabet}},
issn = {{1099-1166}},
language = {{eng}},
pages = {{403--410}},
publisher = {{John Wiley & Sons Inc.}},
series = {{International Journal of Geriatric Psychiatry}},
title = {{Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.}},
url = {{http://dx.doi.org/10.1002/gps.2353}},
doi = {{10.1002/gps.2353}},
volume = {{25}},
year = {{2010}},
}